AI won’t replace PSPs any time soon, but it can amplify their capabilities. Here are five high-impact uses for AI to increase margins and win customers.

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.